Ductal Carcinoma in Situ Clinical Trials

26 recruitingLast updated: June 17, 2026

There are 26 actively recruiting ductal carcinoma in situ clinical trials across 7 countries. Studies span Not Applicable, Phase 2, Phase 1. Top locations include Philadelphia, Pennsylvania, United States, Duarte, California, United States, Kansas City, Kansas, United States. Updated daily from ClinicalTrials.gov.


Ductal Carcinoma in Situ Trials at a Glance

26 actively recruiting trials for ductal carcinoma in situ are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Not Applicable with 9 trials, with the heaviest enrollment activity in Philadelphia, Duarte, and Kansas City. Lead sponsors running ductal carcinoma in situ studies include National Cancer Institute (NCI), Thomas Jefferson University, and University of Florida.

Browse ductal carcinoma in situ trials by phase

Treatments under study

About Ductal Carcinoma in Situ Clinical Trials

Looking for clinical trials for Ductal Carcinoma in Situ? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ductal Carcinoma in Situ trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ductal Carcinoma in Situ clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting
Not Applicable

A Novel Fluorescent Ductal Needle for Localization and Sampling of Micro Lesions in Breast Ducts

Mammary TumorNipple DischargeBreast Ductal Carcinoma in Situ
The Fourth Affiliated Hospital of China Medical University300 enrolled1 locationNCT07339306
Recruiting
Phase 2

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

Ductal Carcinoma in Situ
University of Florida30 enrolled1 locationNCT06868238
Recruiting
Phase 2

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Ductal Carcinoma in Situ
QuantumLeap Healthcare Collaborative400 enrolled28 locationsNCT06075953
Recruiting
Phase 2

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Breast CarcinomaBreast Ductal Carcinoma in SituBreast Atypical Hyperplasia+1 more
National Cancer Institute (NCI)66 enrolled3 locationsNCT06195306
Recruiting
Phase 2

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Breast CarcinomaBreast Ductal Carcinoma in SituBreast Atypical Hyperplasia+1 more
National Cancer Institute (NCI)80 enrolled4 locationsNCT05941520
Recruiting
Phase 2

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast CarcinomaEstrogen Receptor-Positive Breast CarcinomaBreast Ductal Carcinoma in Situ+3 more
National Cancer Institute (NCI)200 enrolled11 locationsNCT06184750
Recruiting

Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery

Invasive Breast CarcinomaBreast Ductal Carcinoma in SituHereditary Breast Carcinoma+1 more
M.D. Anderson Cancer Center600 enrolled4 locationsNCT04169542
Recruiting
Phase 2

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

Estrogen Receptor-Positive Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage 0 Breast Cancer AJCC v8+5 more
City of Hope Medical Center36 enrolled1 locationNCT06538389
Recruiting
Not Applicable

Endoscopic Nipple-Sparing Mastectomy Through a Single Axillary Incision in Breast Cancer

Breast CancerBreast Cancer - Ductal Carcinoma in Situ (DCIS)
Fondazione del Piemonte per l'Oncologia10 enrolled1 locationNCT07507890
Recruiting
Phase 2

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

Breast CancerDuctal Carcinoma in SituEarly Stage Breast Cancer+1 more
UNC Lineberger Comprehensive Cancer Center90 enrolled1 locationNCT06902311
Recruiting

EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients

Breast CancerDuctal Carcinoma in Situ
Thomas Jefferson University200 enrolled1 locationNCT07478016
Recruiting
Phase 1

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Ductal Carcinoma in Situ
Finn, Olivera, PhD50 enrolled1 locationNCT06218303
Recruiting
Phase 1

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

Breast Ductal Carcinoma in Situ
Mayo Clinic43 enrolled2 locationsNCT04144023
Recruiting
Not Applicable

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care

Breast CarcinomaBreast Ductal Carcinoma in Situ
Roswell Park Cancer Institute126 enrolled1 locationNCT06350500
Recruiting
Not Applicable

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Anatomic Stage 0 Breast Cancer AJCC v8Triple-Negative Breast CarcinomaInvasive Breast Carcinoma+4 more
Thomas Jefferson University80 enrolled1 locationNCT04959474
Recruiting
Not Applicable

Identifying and Caring for Individuals With Inherited Cancer Syndrome

Malignant Solid NeoplasmBreast Ductal Carcinoma in SituHematopoietic and Lymphoid System Neoplasm+3 more
OHSU Knight Cancer Institute27,500 enrolled2 locationsNCT04494945
Recruiting

Validation of the Oncoliq Test for the Early Detection of Breast Cancer.

Breast Cancer FemaleBreast Cancer DetectionBreast Cancer Early Stage Breast Cancer (Stage 1-3)+4 more
Oncoliq US Inc300 enrolled1 locationNCT07331506
Recruiting
Not Applicable

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions

Breast CancerDuctal Carcinoma in Situ
University of Florida50 enrolled1 locationNCT06903468
Recruiting
Not Applicable

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

Ductal Carcinoma in SituStage III Breast CancerStage I Breast Cancer+1 more
Barbara Ann Karmanos Cancer Institute30 enrolled1 locationNCT07095114
Recruiting
Not Applicable

Neoadjuvant Breast Cancer Time Restricted Eating

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+4 more
Thomas Jefferson University55 enrolled1 locationNCT05327608